がんモノクローナル抗体の市場規模・シェア・成長分析 (種類別、用途別、エンドユーザー別、地域別)：産業予測 (2024～2031年)

世界のがんモノクローナル抗体の市場規模は、2022年に739億米ドルと評価され、2023年の875億米ドルから2031年には3,379億2,000万米ドルに拡大し、予測期間中 (2024～2031年) に18.40%のCAGRで成長する見通しです。

モノクローナル抗体 (mAb) 療法は、化学療法・放射線療法・外科手術といった従来の治療法を補完する、がん治療における重要な要素であるとの認識が高まっています。過去20年間で、mAbは固形がんと血液悪性腫瘍の両方に非常に効果的な治療法として確立され、がん罹患率の上昇と新薬承認の強力なパイプラインに拍車がかかりました。現在および今後承認される予定のmAb療法は、従来の化学療法に比べて副作用が比較的少ないという治療上の利点があり、世界中の何百万人もの人々に恩恵をもたらす可能性を秘めています。医療提供者による手頃な価格のバイオシミラーモノクローナル抗体の受け入れ拡大により、予測期間中の市場成長はさらに高まると予想されます。しかし、COVID-19の流行はがん検診の受診率に悪影響を及ぼし、2020年4月の乳がん検診受診率は以前と比較して87%の劇的な低下が観察されました。この減少は治療の大幅な遅れをもたらし、必要な抗がん剤へのタイムリーなアクセス、疾患の再発、治療の延期に関する懸念を引き起こしています。がんは依然として、抑制されない細胞増殖を特徴とする主要な慢性疾患であるため、がん罹患率の上昇が今後もmAb治療薬に対する需要を牽引し、市場の拡大を後押しする可能性が高いです。全体として、がん市場のうちmAb分野は、革新的ながん治療へのニーズと、パンデミック後の状況における医療アクセスの進化の両方によって、成長の態勢を整えています。

目次

イントロダクション

• 分析目的
• 定義
• 市場範囲

分析手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模予測
• 市場の想定と制限

エグゼクティブサマリー

• 市場の概要と見通し
• 需給動向の分析
• セグメント別の機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主な市場の考察

• 技術分析
• バリューチェーン分析
• 市場のエコシステム
• ケーススタディ分析
• 規制情勢
• イノベーションマトリクス
• 主な投資の分析
• 主な成功要因
• 競合の程度

がんモノクローナル抗体市場：種類別

• 市場概要
• ヒト化
• ヒト
• キメラ
• マウス

がんモノクローナル抗体市場：用途別

• 市場概要
• 血液がん
• 乳がん
• 肺がん
• 悪性黒色腫
• 大腸がん
• 肝臓がん
• その他

がんモノクローナル抗体市場：エンドユーザー別

• 市場概要
• 病院
• 研究機関
• その他

がんモノクローナル抗体市場：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ
• 中東・アフリカ (MEA)
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング (2023年)
• 主な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア (2023年)

主要企業プロファイル

• AbbVie Inc. (米国)
• Amgen Inc. (米国)
• Merck & Co., Inc. (米国)
• Bristol-Myers Squibb Company (米国)
• Gilead Sciences, Inc. (米国)
• Takeda Pharmaceutical Company (日本)
• AstraZeneca plc (英国)
• Eli Lilly and Company (米国)
• Regeneron Pharmaceuticals, Inc. (米国)
• BeiGene, Ltd (中国)
• Biogen Inc. (米国)
• Recordati Industria Chimica e Farmaceutica S.p.A (イタリア)
• Pfizer (米国)
• Spectrum Pharmaceuticals, Inc. (米国)
• Iovance Biotherapeutics, Inc. (米国)
• Exelixis, Inc. (米国)
• OncoOne (米国)
• CureVac AG (ドイツ)
• Cellerant Therapeutics, Inc. (米国)
• Celltrion, Inc. (韓国)
• Faron Pharmaceuticals Ltd. (フィンランド)

Global Cancer Monoclonal Antibodies Market size was valued at USD 73.9 billion in 2022 and is poised to grow from USD 87.5 billion in 2023 to USD 337.92 billion by 2031, growing at a CAGR of 18.40% during the forecast period (2024-2031).

Monoclonal antibody (mAb) therapies are increasingly recognized as crucial components in the cancer treatment landscape, complementing traditional modalities such as chemotherapy, radiation, and surgery. Over the past two decades, mAbs have established themselves as highly effective treatments for both solid tumors and hematologic malignancies, spurred by rising cancer incidence rates and a robust pipeline of new drug approvals. Current and forthcoming mAb therapies hold the potential to benefit millions globally, offering a therapeutic advantage due to their relatively lower side effects compared to conventional chemotherapy. The growing acceptance of affordable biosimilar monoclonal antibodies by healthcare providers is expected to further enhance market growth in the forecast period. However, the COVID-19 pandemic has negatively impacted cancer screening rates, with a dramatic 87% drop observed in breast cancer screenings in April 2020 compared to previous years. This decline resulted in significant treatment delays, raising concerns about timely access to necessary cancer medications, disease recurrence, and the postponement of therapies. As cancer remains a major chronic disease characterized by unchecked cell proliferation, the escalating incidence of cancer cases will likely continue to drive demand for mAb therapies and bolster market expansion in the coming years. Overall, the mAb segment of the oncology market stands poised for growth, fueled by both the need for innovative cancer treatments and the evolution of healthcare access in a post-pandemic landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Monoclonal Antibodies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Monoclonal Antibodies Market Segmental Analysis

Global Cancer Monoclonal Antibodies Market is segmented by Type, Application, End-user, end user and region. Based on Type, the market is segmented into Humanized, Human, Chimeric, and Murine. Based on Application, the market is segmented into Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, and Others. Based on End-user, the market is segmented into Hospitals, Research Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Cancer Monoclonal Antibodies Market

The Global Cancer Monoclonal Antibodies market is significantly driven by the alarming rise in cancer prevalence worldwide, which underscores the urgent need for innovative and effective treatment options. Monoclonal antibodies are favored over traditional therapies due to their ability to selectively target malignant cells, thereby improving treatment efficacy and minimizing adverse effects. As patient demand for advanced therapeutic solutions escalates, the market is further bolstered by increased investments in research and development aimed at discovering novel monoclonal antibody-based therapies. Furthermore, heightened awareness surrounding cancer leads to earlier detection and treatment initiation, propelling growth and development within this vital sector of oncology.

Restraints in the Global Cancer Monoclonal Antibodies Market

A significant market restraint for the global cancer monoclonal antibodies market is the prohibitively high cost associated with monoclonal antibody therapies. The advanced manufacturing processes and extensive research and development required for these therapies contribute to their steep pricing. This financial burden limits patient access, particularly among low-income communities and in countries with strained healthcare budgets. As a result, the expensive nature of these treatments may render them unaffordable for many, leading to increased out-of-pocket expenses and further hindering market growth and accessibility. This economic barrier could ultimately restrict the adoption of these potentially life-saving therapies across diverse populations.

Market Trends of the Global Cancer Monoclonal Antibodies Market

The Global Cancer Monoclonal Antibodies market is witnessing a significant trend towards the integration of combination therapies, reflecting an evolving landscape in oncology treatment. By leveraging monoclonal antibodies in conjunction with immunotherapies, targeted therapies, and chemotherapy, healthcare providers aim to combat cancer on multiple fronts, enhancing treatment efficacy while minimizing resistance. The synergistic effects observed, particularly with immune checkpoint inhibitors paired with monoclonal antibodies, underscore the potential for improved patient outcomes through deeper immune responses against tumors. This trend not only highlights the complexity of cancer but also emphasizes the shift towards personalized medicine, offering tailored and potent treatment options for diverse patient profiles.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Cancer Monoclonal Antibodies Market by Type

• Market Overview
• Humanized
• Human
• Chimeric
• Murine

Cancer Monoclonal Antibodies Market by Application

• Market Overview
• Blood Cancer
• Breast Cancer
• Lung Cancer
• Melanoma
• Colorectal Cancer
• Liver Cancer
• Others

Cancer Monoclonal Antibodies Market by End-user

• Market Overview
• Hospitals
• Research Institutes
• Others

Cancer Monoclonal Antibodies Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recordati Industria Chimica e Farmaceutica S.p.A (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Biotherapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OncoOne (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CureVac AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellerant Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Faron Pharmaceuticals Ltd. (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments